What is Avalo Therapeutics's return on equity?

Avalo Therapeutics (AVTX) reported return on equity of -88.8% in Q1 2026.

What is the long-term trend for Avalo Therapeutics's return on equity?

Over 3 years (2020 to 2025), Avalo Therapeutics's return on equity has grown at a -36.2% compound annual growth rate (CAGR), from -278.8% to -72.4%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Avalo Therapeutics AVTX Return on equity

Return on equity at other companies

Eli LillyLLY

107.6%+29.9pp

AbbVieABBV

89%+32.7pp

XencorXNCR

-29.8%-2.7pp

AbCellera Biologics Inc.ABCL

-14.7%-0.8pp

AnaptysBio, Inc.ANAB

-343.8%-1,012pp

Absci CorporationABSI

-63.9%+28.0pp

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Calculated from Avalo Therapeutics’s reported figures.

net income/total stockholders equity=-88.8%

Based on trailing twelve months.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's return on equity?: Avalo Therapeutics (AVTX) reported return on equity of -88.8% in Q1 2026.
What is the long-term trend for Avalo Therapeutics's return on equity?: Over 3 years (2020 to 2025), Avalo Therapeutics's return on equity has grown at a -36.2% compound annual growth rate (CAGR), from -278.8% to -72.4%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.